Building Clinical Capacity for Integration of Blood‐Based Biomarkers in Early Detection of Alzheimer's Disease
Released On
November 14, 2025
Expires On
November 14, 2026
Media Type
Internet
Completion Time
Up to 3.0 hours
Specialty
Neurology, Primary Care
Topic(s)
Alzheimer's, Dementia, Geriatric Medicine
Providers/Grant Support:
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Lilly.
Credit Available
- Physicians — maximum of 3.0 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is intended for primary care providers and general neurologists who most frequently encounter individuals with or at risk for mild cognitive impairment (MCI) and dementia.
Program Overview
Cognitive impairment and dementia due to Alzheimer's disease (AD) pose a significant public health challenge as the population of older adults in the United States continues to grow. AD is now understood as a continuum rather than a discrete clinical entity, with pathologic changes beginning several years or even decades before the onset of cognitive symptoms. This concept has revolutionized the understanding of AD progression, and newly revised criteria for the diagnosis and staging of AD reflect these advances. In addition, the recent development and approval of blood-based biomarker tests (BBMs) can further enhance patient care through detection of pathologic changes to facilitate earlier diagnosis in symptomatic individuals. However, although BBMs offer an accessible and more cost-effective method for diagnosis of AD compared with traditional tests (ie, cerebrospinal fluid tests and imaging), effective integration of BBMs into routine clinical practice requires standardization through development of protocols and clinical pathways and training of clinical teams.
Considering the rapid advances in this field, providers in both primary care and general neurology settings need to know who to test, when to test, which test to use, and how to interpret the results. To support primary care providers and neurologists in navigating this complexity and to support peer-to-peer learning, this training program, modeled on the CDC Training of Trainers approach, provides learners with the tools and resources to implement BBM testing in clinical practice to improve earlier diagnosis of AD.
Learning Objectives
Upon completion of this activity, learners will be able to:
- Outline the clinical continuum of cognitive decline in AD
- Describe the role blood-based biomarkers can fill in the updated criteria for AD diagnosis and staging
- Develop and implement diagnostic protocols to integrate blood biomarker testing into routine clinical practice
- Identify ongoing opportunities to improve clinical care pathways in patients exhibiting early signs of cognitive changes
Faculty
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
Suzanne E. Schindler, MD, PhD
Associate Professor of Neurology
Washington University School of Medicine
St. Louis, MO
Chuck Vega, MD
Clinical Professor, Assistant Dean
University of California, Irvine
Santa Ana, CA
The following financial relationships have been provided:
Suzanne Schindler, MD, PhD
Advisory Board: Eisai, Novo Nordisk
Speakers' Bureau: Eli Lilly, Eisai, Novo Nordisk
Chuck Vega, MD
Consultant: Boehringer Ingelheim, Exact Sciences, GlaxoSmithKline Pharmaceuticals
Accreditation Statement
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Disclosures of Conflicts of Interest
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take up to 3.0 hours to complete. To receive credit, learners are required to complete an assessment, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Laurie Novoryta at [email protected].
Disclosure of Unlabeled Use:
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: PrecivityAD2, ALZpath Quanterix, and LucentAD Quanterix tests are not approved by the FDA.
Disclaimer
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Pharmacists should consult with their state pharmacy on pharmacist vaccination authority included within their scope of practice.
Contact Information
For questions, contact Laurie Novoryta at [email protected].